LIN, JEN CHENG,林仁政,林仁政,TSAI, JUI-CHI,蔡瑞骐,蔡瑞騏,HSIEH, PEI JUNG,谢佩蓉,謝佩蓉,DU, YING-CHI,杜英齐,杜英齊
申请号：
TW106125621
公开号：
TW201805001A
申请日:
2017.07.28
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention relates to a novel type of BAX/BCL-2 modulator having a pyrimido[5,4-d]pyrimidine main structure. The BAX/BCL-2 modulator can enhance the expression and activity of BAX/BCL-2 in cells. The present invention also relates to a pharmaceutical composition comprising the BAX/BCL-2 modulator of the invention encapsulated in a pharmaceutically acceptable carrier so that it can be directly delivered into cells. The present invention thus provides a method of preventing or treating BAX/BCL-2-related disorders or conditions comprising administering to a subject in need thereof a therapeutically effective amount of the BAX/BCL-2 modulator of the invention or the pharmaceutical composition of the invention.本發明係關於具有嘧啶并[5,4-d]嘧啶主要結構之新穎類型BAX/BCL-2調節劑。該BAX/BCL-2調節劑可增強細胞中之BAX/BCL-2之表現及活性。本發明亦係關於醫藥組合物,其包含囊封於醫藥上可接受之載劑中之本發明BAX/BCL-2調節劑,以使得其可直接遞送至細胞中。因此,本發明提供預防或治療BAX/BCL-2相關病症或病況之方法,其包含向需要其之個體投與治療有效量之本發明之BAX/BCL-2調節劑或本發明之醫藥組合物。
